Prothrombin Knockdown Protects Podocytes and Reduces Proteinuria in Glomerular Disease

Area of Science:

• Nephrology
• Hematology
• Cardiovascular Research

Background:

• Chronic kidney disease (CKD) progression is linked to glomerular podocyte injury and loss, leading to proteinuria.
• Proteinuria and CKD increase the risk of thromboembolic disease, with thrombin known to injure podocytes.
• The direct impact of circulating prothrombin on glomerular pathology remained unclear.

Purpose of the Study:

• To investigate the influence of circulating prothrombin on glomerular pathobiology in a rat model of kidney disease.
• To test the hypothesis that prothrombin drives podocytopathy, podocytopenia, and proteinuria.

Main Methods:

• Induced glomerular proteinuria in Wistar rats using puromycin aminonucleoside (PAN).
• Modulated circulating prothrombin levels using antisense oligonucleotides (hypoprothrombinemia) or prothrombin infusions (hyperprothrombinemia).
• Assessed kidney pathology, podocyte injury/loss, proteinuria, and plasma albumin levels.

Main Results:

• Prothrombin knockdown significantly reduced prothrombin co-localization to podocytes, podocytopathy, podocytopenia, and proteinuria, improving plasma albumin.
• Hyperprothrombinemia significantly increased podocytopathy and proteinuria compared to controls.
• Podocytopenia was significantly reduced in rats with low prothrombin levels versus those with high prothrombin levels.

Conclusions:

• Prothrombin knockdown ameliorated PAN-induced glomerular disease, while hyperprothrombinemia exacerbated it.
• Circulating prothrombin directly influences podocyte injury and kidney disease progression.
• Prothrombin antagonism presents a potential dual strategy for thromboprophylaxis and preventing CKD progression.